Gilead acquired Livdelzi – an oral PPAR delta agonist – as the main asset in its $4.3 billion takeover of CymaBay Therapeutics in February. Prior to that, it was in development for metabolic ...

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

Fibrates are widely prescribed agonists of transcription factor peroxisome proliferator-activated receptor (PPAR)-α, and are used to treat patients with atherogenic dyslipidemia. These drugs ...

In light of the poor performance and late-stage failures of some drugs targeting PPARs, Gromo says it is important to recognize that all PPAR agonists are unique, and each has different benefits ...